While the pharmaceutical space has been generating hefty returns for investors since the start of the year, shares of Teva Pharmaceuticals (TEVA 0.10%) are up a mere 2.7%. Compare that with Dow component Pfizer, which has soared almost 14%, and generic-drug maker Mylan, up 42% since the start of 2013, and it's clear that something serious is muting Teva's growth. In the following video from The Motley Fool's health-care show Market Checkup, analysts David Williamson and Max Macaluso discuss the major competitive threats confronting Teva today.
Key Problems Behind Teva's Lackluster 2013
By Max Macaluso and Dave Williamson – Sep 15, 2013 at 7:30AM
NYSE: TEVA
Teva Pharmaceutical Industries
Market Cap
$22B
Today's Change
(-0.10%) $0.02
Current Price
$18.97
Price as of October 22, 2025 at 4:00 PM ET
Why are shares of Teva up only 2.7% since the start of 2013?
About the Author
Max is the Technology, Biopharma & Health Care Bureau Chief at Fool.com. Prior to joining the Fool, he completed a PhD in chemistry at the University of Cambridge and an MBA at the College des Ingenieurs.
Follow @TMFMassimo